Effect of melatonin on serum cholesterol and phospholipid levels, and on prolactin, thyroid-stimulating hormone and thyroid hormone levels, in hyperprolactinemic rats

Esquifino, Ana I.; Agrasal, C.; Velázquez, Esther; Villanúa, María Ángeles; Cardinali, D.P.

doi:10.1016/s0024-3205(97)00613-9

Cited by 36 publications

(26 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, as shown in animal studies, several mechanisms can be responsible for the hypolipidemic effects of melatonin, e.g. decrease in intestinal cholesterol absorption [56], inhibition of cholesterol biosynthesis and interaction with LDL cholesterol receptors [57] or augmentation of lecithin-cholesterol acyltransferase-mediated cholesterol esterification [58]. Melatonin ameliorates nonalcoholic fatty liver induced by a high-fat diet in rats that may also affect serum lipids [59].…”

Section: Clinical Studies Using Melatonin In Msmentioning

confidence: 99%

Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications

et al. 2011

View full text Add to dashboard Cite

Metabolic syndrome (MS) patients exhibit sleep/wake disturbances and other circadian abnormalities, and these may be associated with more rapid weight increase and development of diabetes and atherosclerotic disease. On this basis, the successful management of MS may require an ideal drug that besides antagonizing the trigger factors of MS could also correct the disturbed sleep-wake rhythm. Melatonin is an effective chronobiotic agent able to change the phase and amplitude of circadian rhythms. Melatonin has also significant cytoprotective properties preventing a number of MS sequelae in animal models of diabetes and obesity. A small number of controlled trials indicate that melatonin is useful to treat the metabolic and cardiovascular comorbidities of MS. Whether the recently introduced melatonergic agents (ramelteon, agomelatine, tasimelteon) have the potential for treating sleep disorders in MS patients and, more generally, for arresting the progression of disease, merits further investigation.

show abstract

Section: Clinical Studies Using Melatonin In Msmentioning

confidence: 99%

Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In genetically and diet-induced hypercholesterolemic rats MEL administration decreased serum cholesterol (Aoyama et al 1988;Mori et al 1989). Esquifino et al (1997) recorded a decrease in cholesterol in the serum, liver, adrenal glands and testes after pineal extract administration to hyperprolactinemic rats while pinealectomy had the opposite effect. Pharmacological doses of MEL administered in tap water during a period of 3 months reduced increased concentrations of total and LDL-cholesterol and increased plasma HDLcholesterol in young rats fed hypercholesterolemic diet.…”

mentioning

confidence: 94%

Effect of Low-dose Chronic Melatonin Administration on Metabolic and Hormonal Variables of Young Laboratory Rats

Marková¹,

Adámeková²,

Bojková³

et al. 2004

Acta Vet. Brno

View full text Add to dashboard Cite

Marková M., E. Adámeková, B. Bojková, P. Kubatka, M. Kassayová, E. Ahlersová, I. Ahlers: Effect of Low-dose Chronic Melatonin Administration on Metabolic and Hormonal Variables in Young Laboratory Rats. Acta Vet. Brno 2004, 73: 445-453.The introduction of melatonin (MEL) as a drug remains open due to insufficient data about the effects of its long-term administration on metabolism. We explored effects of MEL given for 26 weeks at low doses, 4 µg/ml of tap water, on selected metabolic and hormonal indices in young female and male Sprague-Dawley rats.Male and female rats aged 5 weeks were adapted to standard housing conditions and artificial light regimen L:D = 12:12 h. The animals were fed standard laboratory diet and drank tap water (controls) or MEL solution ad libitum. Body weight gain, food and water intake was regularly recorded. Oral glucose tolerance tests (OGTTs) were carried out before and 24 weeks after MEL administration. At the end of the experiment following an overnight fast the animals were sacrificed, selected organs and tissues were weighed, selected metabolic indices and hormone concentrations were determined in the serum, liver, heart muscle and bone marrow (femur).Chronic MEL administration increased in females serum corticosterone concentration, decreased glycogen concentration in the liver and heart muscle, increased triacylglycerol concentration in the bone marrow. An increased absolute weight of periovarial fat and body weight gain were found in last 5 weeks of the experiment. In males, MEL decreased insulin concentration in the serum and body weight gain from week 2 to week 17 of its administration; it decreased relative liver weight in males and females. MEL did not alter food or water intake in both sexes. MEL treatment decreased glucose tolerance (i.e. reduced area under curve values in OGTTs) in males and prolonged the return of afterload glycemia values to initial level in females.Alterations of carbohydrate metabolism regulation and of body weigth gain were found in both sexes of young rats after long term melatonin administration.

show abstract

“…It has also been shown that the ability of LCAT to esterify F-Chol in the plasma of ANIT-treated rats with cholestasis is reduced by a defect of Apo A-1 activation [4]. Esquifino et al [9] reported that a decrease in F-Chol concentration occurs with a concomitant increase in the percentage of E-Chol concentration to T-Chol concentration, in the serum of normal rats injected with MT for 4 days, although there is no change in serum T-Chol concentration. Therefore, there is a possibility that a single oral administration of MT to ANIT-treated rats attenuates the reduced ability to convert F-Chol to E-Chol via LCAT activated by Apo A-1 in the serum.…”

Section: Discussionmentioning

confidence: 99%

Effect of melatonin on serum cholesterol status with formation of alpha-naphthylisothiocyanate-induced liver injury in rats

Ohta

Imai

Kitagawa

2007

International Congress Series

View full text Add to dashboard Cite

Effect of melatonin on serum cholesterol and phospholipid levels, and on prolactin, thyroid-stimulating hormone and thyroid hormone levels, in hyperprolactinemic rats

Cited by 36 publications

References 11 publications

Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications

Melatonin and the Metabolic Syndrome: Physiopathologic and Therapeutical Implications

Effect of Low-dose Chronic Melatonin Administration on Metabolic and Hormonal Variables of Young Laboratory Rats

Effect of melatonin on serum cholesterol status with formation of alpha-naphthylisothiocyanate-induced liver injury in rats

Contact Info

Product

Resources

About